Single-dose methotrexate injection for treatment of ectopic pregnancy in women with relatively low levels of human chorionic gonadotropin

Krissi, Haim; Peled, Yoav; Eitan, Ram; Bishara, Amani; Goldchmit, Chen; Ben-Haroush, Avi

doi:10.1016/j.ijgo.2012.11.020

“…Dans l'étude de Krissi [25], il n'y avait aucune grossesse extra-utérine comprenant un embryon avec activité cardiaque dans le groupe de 76 patientes pour qu'une seule injection de méthotrexate a été suffisante. Dans le groupe « échec après la première injection de méthotrexate », 3 patientes sur 26 avaient une grossesse extra-utérine porteuse d'un embryon avec une activité cardiaque.…”

Section: Selon Le Résultat De L'échographieunclassified

“…La médiane du diamètre maximal de l'hémopéritoine mesuré sur un cliché sagittal du cul de sac de Douglas était à 30 mm [22][23][24][25][26][27][28][29][30][31][32]. Les 8 patientes ont été traitées avec succès, six par l'expectative et deux par une injection unique de méthotrexate.…”

Section: Les Contre-indications Du Méthotrexate Dans La Geu Tubaireunclassified

Utilisation du méthotrexate dans les GEU tubaires

Lesavre

¹

,

Curinier

²

,

Capmas

³

et al. 2015

Journal de Gynécologie Obstétrique et Biologie de la Reproducti

View full text Add to dashboard Cite

“…Since the first publication by Tanaka et al [13], the use of MTX for the treatment of women with unruptured EP has become common practice [14]. The successful treatment of EP depends on several factors, including the serum hCG level, route of MTX administration, size of the ectopic mass and FCA [15][16][17]. However, the effect of luteal blood flow during pregnancy on MTX treatment in women with EP has not been previously reported.…”

Section: Discussionmentioning

confidence: 99%

Luteal blood flow as a predictive factor for methotrexate treatment outcomes in women with unruptured tubal pregnancy

Wang

¹

,

Pei

²

,

Yang

³

et al. 2020

Preprint

0

View full text Add to dashboard Cite

Background: Blood flow in the corpus luteum is associated with luteal function. However, the impact of luteal blood flow on methotrexate (MTX) treatment in women with unruptured tubal pregnancy has not been reported. The aim of the present study was to observe the impact of luteal blood flow on the therapeutic effect of MTX in women with unruptured tubal pregnancy. Methods: A prospective observational study recruited 129 women with unruptured tubal pregnancy in the First Affiliated Hospital of Xi’an Jiaotong University from September 2016 to June 2018. One hundred and fifteen women were treated successfully with MTX, and women were divided into 2 groups according to luteal blood flow: the poor luteal blood flow group and the abundant luteal blood flow group. The therapeutic effects were compared between the two groups. Results: Women in the abundant luteal blood flow group had a significantly higher serum β-human chorionic gonadotropin (β-hCG) level 4 days, 1 week and 2 weeks after MTX treatment compared with women in the poor luteal blood flow group ( P <0.05). The average diameter of the ectopic mass 1 week, 2 weeks and 3 weeks after MTX treatment in women with abundant luteal blood flow was significantly larger ( P <0.05), and the time of serum β-hCG clearance and ectopic mass disappearance were significantly longer compared with those in women in the poor luteal blood flow group ( P <0.05). Conclusions: Luteal blood flow might be a predictive factor for MTX treatment outcomes in women with unruptured tubal pregnancy, and those with abundant luteal blood flow need a longer recovery time.

show abstract

“…Since the first application by Tanaka et al [13], MTX has become the primary treatment for unruptured EP [14]. The successful treatment of EP depends on several factors, including the serum hCG level, route of MTX administration, size of the ectopic mass and FCA [15][16][17]. However, the effect of luteal blood flow during pregnancy on MTX treatment in women with EP has not been previously reported.…”

Section: Discussionmentioning

confidence: 99%

Luteal blood flow as a predictive factor for methotrexate treatment outcomes in women with unruptured tubal pregnancy

Wang

¹

,

Pei

²

,

Yang

³

et al. 2020

Preprint

0

View full text Add to dashboard Cite

Background: Blood flow in the corpus luteum is associated with luteal function. However, the impact of luteal blood flow on methotrexate (MTX) treatment in women with unruptured tubal pregnancy has not been reported. The aim of the present study was to observe the impact of luteal blood flow on the therapeutic effect of MTX in women with unruptured tubal pregnancy. Methods: A prospective observational study recruited 129 women with unruptured tubal pregnancy in the First Affiliated Hospital of Xi’an Jiaotong University from September 2016 to June 2018. One hundred and fifteen women were treated successfully with MTX, and women were divided into 2 groups according to luteal blood flow: the poor luteal blood flow group and the abundant luteal blood flow group. The therapeutic effects were compared between the two groups. Results: Women in the abundant luteal blood flow group had a significantly higher serum β-human chorionic gonadotropin (β-hCG) level 4 days, 1 week and 2 weeks after MTX treatment compared with women in the poor luteal blood flow group ( P <0.05). The average diameter of the ectopic mass 1 week, 2 weeks and 3 weeks after MTX treatment in women with abundant luteal blood flow was significantly larger ( P <0.05), and the time of serum β-hCG clearance and ectopic mass disappearance were significantly longer compared with those in women in the poor luteal blood flow group ( P <0.05). Conclusions: Luteal blood flow might be a predictive factor for MTX treatment outcomes in women with unruptured tubal pregnancy, and those with abundant luteal blood flow need a longer recovery time.

show abstract

Single-dose methotrexate injection for treatment of ectopic pregnancy in women with relatively low levels of human chorionic gonadotropin

Abstract: In patients with ectopic pregnancy and relatively low levels of serum hCG, the most important predictors of overall failure of methotrexate injection were the presence of a yolk sac and mass size.

Cited by 19 publications

References 11 publications

Utilisation du méthotrexate dans les GEU tubaires

Utilisation du méthotrexate dans les GEU tubaires

Luteal blood flow as a predictive factor for methotrexate treatment outcomes in women with unruptured tubal pregnancy

Luteal blood flow as a predictive factor for methotrexate treatment outcomes in women with unruptured tubal pregnancy

Contact Info

Product

Resources

About